Canada: Andersen v. St. Jude Medical: Whither Waiver Of Tort?

Class action litigants have long been awaiting a trial decision that would tackle the controversial doctrine of waiver of tort.

At the certification stage of proposed class proceedings, plaintiffs have been asserting waiver of tort alongside negligence and other tort claims, arguing that the waiver of tort doctrine should allow the court to order defendants to account for and disgorge the profits gained from the impugned conduct if a finding of negligence is made. This would effectively eliminate the traditional need for claimants to prove injury or loss in order to obtain an order for payment of damages. Most judges have punted the tough questions regarding waiver of tort to trial, on the theory that a full factual record was needed to decide them.

On June 26, 2012, Justice Lax of the Ontario Superior Court of Justice issued the decision in Andersen v. St. Jude Medical.1 Having found for the defendants, Justice Lax declined to decide this policy issue and expressly noted that the full factual record in this long common issues trial was not helpful in deciding the issue. It is hoped that this guidance will lead quickly to much-needed clarity in this important area. The case is also noteworthy for the approach taken in several other important aspects of class action product liability cases.


Andersen involved a claim against a global manufacturer of mechanical prosthetic heart valves. At its core, this was a negligence claim, focusing on whether there had been a breach of duty causing injury. Following 138 days of trial evidence and several months of legal arguments, Justice Lax dismissed the plaintiffs' claim in its entirety. The lengthy, thoughtful decision provides guidance on the role of scientific experts, epidemiological studies, and proof of causation through scientific expert evidence, in addition to tackling the doctrine of waiver of tort.

At issue was a prosthetic heart valve with a cuff coated with a proprietary mixture called "Silzone." The Silzone valve was designed to directly reduce the incidence of post-operative infection by inhibiting the growth of bacteria. The plaintiffs alleged that Silzone interfered with tissue healing and impaired the body's ability to incorporate the device into the heart properly, leading to serious medical complications.

In January 2000, St. Jude voluntarily recalled all Silzone-coated products after its own ongoing randomized clinical trial, AVERT, revealed a small but statistically significant increase in a medical complication. 

Approach to Expert Evidence

A key issue in the case was the reliability of the scientific experts. Justice Lax assessed the extensive expert evidence on the basis of a generally accepted hierarchy within the scientific literature of epidemiological studies that help investigate causal relationships.2 The defendants' experts relied primarily on data from the AVERT study, a randomized clinical trial considered to be at the top of the hierarchy. The plaintiffs' experts relied on data from cohort studies, case studies, and case reports, which were not as robust and thus lower in the hierarchy.

Breach of Standard of Care

The plaintiffs alleged that St. Jude's testing of Silzone was inadequate and that Silzone was rushed onto the market. The parties agreed that, in determining whether Silzone should be made available to the market, St. Jude was required to perform a risk utility assessment. This assessment requires the manufacturer to weigh both the gravity and likelihood of the reasonably foreseeable risks posed by the product, relative to the potential extent of its utility and the likelihood that the potential utility could be realized.3

Justice Lax found no evidence that Silzone was rushed onto the market at the expense of completing appropriate product evaluation, despite the plaintiffs' assertions that St. Jude prioritized profits over product safety. She noted that, while it would be naïve to think the company was unconcerned by profit, this does not mean St. Jude fell below the standard of care.4

Justice Lax concluded that there was a demand for an antimicrobial heart valve and St. Jude had appropriately tested and weighed the potential utility of Silzone with its risks.  She found that the plaintiffs had not shown that additional tests were possible or would have affected the risk utility assessment.

The Court also considered whether St. Jude effectively monitored the Silzone products so as to issue warnings and/or recall the product within a reasonable timeframe. Significantly, St. Jude had already warned of the adverse events alleged by the plaintiffs in its labeling and physicians' manual. Justice Lax found that St. Jude met its standard of care by investigating concerns, sending out a "Dear Doctor" letter, and maintaining an open dialogue with Health Canada and the FDA. When the AVERT study began to yield data that raised concerns, St. Jude ended enrolment in AVERT and issued a recall of Silzone products. Prior to this time, the available information did not indicate an additional risk that would have reasonably required an updated warning or some other action.


Justice Lax's findings on causation, specifically, whether Silzone materially contributed to medical complications, were made largely on the expert evidence. Justice Lax decided that the scientific literature supported the conclusion that Silzone does not materially increase the risk of medical complications.

To determine materiality, Justice Lax would have applied a risk ratio of 2.0, meaning the probability of developing a medical complication was double when Silzone patients were compared with non-Silzone patients. In effect, if the epidemiological evidence demonstrated a risk ratio above 2.0, this would presumptively determine causation on a balance of probabilities, absent evidence presented by the defendant to rebut the presumption; a risk ratio below 2.0 would presumptively disprove causation, absent individualized evidence presented by a class member to rebut the presumption.5 This serves as useful guidance on available approaches to determining causation in a class action context, as more class actions begin to proceed to trials on the merits.

Waiver of Tort

Allowing claims based on waiver of tort essentially eliminates the plaintiff's need to prove loss, so long as the plaintiff proves that the defendant engaged in some wrongdoing. Deciding on the types of wrongdoing to which it should apply engages policy concerns about the role of tort law as a compensatory mechanism. At trial, Professor Michael Trebilcock put forward the opinion that the waiver of tort doctrine would create a "super-compensatory" regime whereby plaintiffs could be overcompensated if the defendant's gain from its wrongful conduct exceeded the damages suffered by the plaintiffs. He testified that this was undesirable because it would destabilize the deterrence and insurance functions of tort law and could deter socially productive activities.6 

Justice Lax found no wrongdoing by St. Jude and therefore did not need to consider liability under the waiver of tort doctrine. She stated, however, that her experience from the trial indicated that a full factual record was not required in order to resolve the waiver of tort debate, and indeed may not require evidence at all – ultimately, it is a policy decision that hopefully will be made in the near future.


The Andersen decision is one more milestone in Canadian class proceedings and represents a further maturation of the class action regime under the Class Proceedings Act, 1992. It evidences the complexity inherent in a common issues trial, particularly one that is largely driven by expert evidence. Further, Andersen is among the growing list of cases such as Kerr v.Danier Leather and Pearson v. Inco, which reflect that a win for the plaintiffs at certification is merely the first step in a long road with many risks.


Andersen v. St. Jude Medical, Inc., 2012 ONSC 3660 (Andersen).

Andersen at paras. 48 and 366, as articulated in Rothwell v. Raes, (1988) 66 OR 449 (HCJ), aff'd (1990) 2 OR (3d) 332 (CA), leave to appeal refused [1991] SCCA No 58.

Andersen at para. 62.

Andersen at paras. 73-74.

5  Andersen at para. 556.

6  For example, Professor Trebilcock explained that allowing waiver of tort in negligence cases may cause sellers to take socially excessive precautions on the market, take products off the market, under-invest in product innovation, and charge higher prices.

David Morritt was called to the Bar of Ontario in 1984 after serving as law clerk to Mr. Justice Estey at the Supreme Court of Canada. Sonia Bjorkquist has extensive experience in trial advocacy with expertise in commercial arbitration and the defence of large class actions. Lauren Tomasich practices corporate-commercial civil litigation, with particular emphasis on class actions defence, securities litigation and product liability matters. Patrick Welsh has a broad corporate-commercial litigation and dispute resolution practice, with experience in environmental law and litigation and environmental due diligence.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.